PreveCeutical Medical Inc · CSE:PREV
PreveCeutical Medical — Investor Presentation (September 2017)
28 slides from PreveCeutical Medical's investor presentation, Sep 27, 2017
Slide 1: Investor Deck
CSE: PREV OTCQB: PRVCF FSE: 18H INVESTOR DECK SEPTEMBER 27, 2017 WWW.PREVECEUTICAL.COM
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical™ Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE:18H). The Presentation and its contents are strictly confidential and may not be reproduced o
Slide 3: What We Believe
WHAT WE BELIEVE PreveCeutical Medical Inc., led by an experienced team of senior executives and scientists, believes the medical community is transitioning from a system which “fixed people after they become ill” to one of precision, preventive based, medicine. With this focus, PreveCeutical is comm
Slide 4: What We Are Up To
WHAT WE ARE UP TO 2016 2017 2018 2019 What’s next? Current Homeopathic CELLB9® Digital Therapeutic • International distribution Medicines & Supplements • Developed Marketing Product agreements • Trademarked Program Joint Venture • Product extensions Commences. • Marketing partnerships What’s next? C
Slide 5: R&D Programs at a Glance
R&D PROGRAMS AT A GLANCE Partnered Research and Development programs with UniQuest, the main commercialisation company for the University of Queensland. Under the agreements, intellectual property arising from the carrying out of, results developed during, or created by the programs will be owned by
Slide 6: Peer Comparisons
PEER COMPARISONS COMPANY VALUATIONS & PIPELINES COMPANY / INDUSTRY PRE-CLINICAL PHASE I PHASE II PHASE III NDA Small Molecule/Peptides Genmab Market Cap: USD 14 Billion1 Drug Name: Tisotumab vedotin (HuMax®-TF-ADC) • Proposed Indication: solid tumours (ovary, cervix, endometrium, Share Price: USD 23
Slide 7: Market Opportunities
MARKET OPPORTUNITIES MEETING CURRENT UNMET NEEDS Developing nature identical drugs derived from Blue The global market for cancer treatments Scorpion Venom that treat, regulate and prevent cancer $107 Bn in 20151 progression. Precision treatments for early stage tumors Projections – $161.30 Bn by 20
Slide 8: Research Team
RESEARCH TEAM Our pre-clinical programs are led by Dr. Mak Jawadekar (CSO), having 28 years’ experience with Pfizer Inc., most recently as Pfizer’s Director of Portfolio Management. Dr. Jawadekar’s experience with external partnerships and alliances for research and drug development will be intrumen
Slide 9: Research Team
RESEARCH TEAM Dr. Harendra (Harry) Parekh, Ph.D, BSc. Hons I – Chief Research Officer Based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), Dr. Parekh also holds adjunct positions at the National University of Singapore, and Manipal University, India. Dr. Parek
Slide 10: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Acid Theranostics group, as a McCusker Research Fellow with the Perron Institute for Neurological and Translational Science, based at the Centre for Comparative Genomics at Murdoch University (Perth, Australia). He is an emergi
Slide 11: Nature Identical™ Peptide Research Program
NATURE IDENTICAL™ PEPTIDE RESEARCH PROGRAM PreveCeutical’s scientists will use proprietary chemistry to generate Nature Identical™ peptides, consisting of a library of modified peptide analogues, which will then be tested in disease models. Currently underway, phase one (of three distinct phases) to
Slide 12: Peptide R&D Program
PEPTIDE R&D PROGRAM NON-ADDICTIVE ANALGESICS Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is expected to undergo an expansion in the foreseeable future.
Slide 13: Sol-Gel Delivery Platform
SOL-GEL DELIVERY PLATFORM Developing the first nose to brain delivery system of cannabinoids (CBDs) § Provide clinical relief across a range of indications from pain, inflammation, seizures and neurological disorders. § Proprietary formulation intended for delivery via a nasal spray. § Extended rele
Slide 14: Dual Gene Therapy for Diabetes & Obesity
DUAL GENE THERAPY FOR DIABETES & OBESITY PreveCeutical is working with four leading Australian research centers to co-develop a potential cure for diabetes and obesity. CSE: PREV | OTCQB: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 14
Slide 15: About the Gene Therapy Development Program
ABOUT THE GENE THERAPY DEVELOPMENT PROGRAM PreveCeutical is commencing ground-breaking research targeting a gene therapy cure for type-2 diabetes and obesity. By taking a gene silencing approach by selectively targeting the gene that encodes for the protein PTP-1B, reducing PTB-1B protein levels, th
Slide 16: Diabetes: Facts & Figures
DIABETES: FACTS & FIGURES KILLS ONE PERSON EVERY SIX SECONDS1 2015 GLOBAL EXPENDITURE USD $673 Bn 2040 PROJECTIONS USD $802 Bn1 LOSSES IN GDP WORLDWIDE FROM 2011 – 2030 USD $1.7 TRILLION2 Europe1 2015 59.8 million 2040 71.1 million North America and Caribbean1 2015 44.3 million 2040 60.5 million Mid
Slide 17: Diabetes: Current Drug Therapies vs. Gene Therapy
DIABETES: CURRENT DRUG THERAPIES VS. GENE THERAPY • Currently prescribed anti-diabetic drug • Our dual gene therapy approach targets a therapies universally aim to reduce blood key protein (PTP-1B) implicated and over- glucose levels by targeting one or more of the produced by the key insulin sensit
Slide 18: The Next Phase Through to Preclinical Evaluation
THE NEXT PHASE THROUGH TO PRECLINICAL EVALUATION The multi-disciplinary team have mapped the next phase of the project, which spans 4 years, and encompasses 5 key aims. AIM 1: Engineer a panel of novel, ligand-targeted (i.e. liver, skeletal muscle, fatty tissue and brain) bio-responsive gene carrier
Slide 19: Therapeutic Product - TBI
THERAPEUTIC PRODUCT - TBI JOINT VENTURE WITH SPORTS 1 MARKETING Joint Venture established to develop a therapeutic product geared towards athletes who suffer from concussions (mild traumatic brain injury or TBI). PreveCeutical and Sports 1 Marketing believe that there is therapeutic potential in the
Slide 20: Leadership Team
LEADERSHIP TEAM Stephen Van Deventer - Chairman & Chief ExecutiveOfficer Mr. Van Deventer is an experienced businessman and corporate director. Specializing in international corporate relations and business development over the last twenty five years, Mr. Van Deventer has focused on launching small
Slide 21: Leadership Team
LEADERSHIP TEAM Greg S. Reid-Director Filmmaker and Keynote Speaker Greg S. Reid is a #1 best-selling author, entrepreneur, and the CEO of several successful corporations, who has dedicated his life to helping others achieve the ultimate fulfillment of finding and living a life of purpose. In additi
Slide 22: Leadership Team
LEADERSHIP TEAM Mak Jawadekar Ph.D. - Chief ScienceOfficer Dr. Mak Jawadekar worked at Pfizer Inc. in Groton-New London, Connecticut, for 28 consecutive years more recently as a Director of Portfolio Management. He was responsiblefor Drug Delivery Technology Assessment function involving external ‘D
Slide 23: Leadership Team
LEADERSHIP TEAM Alicia Rebman – VP Marketing &Advertising Ms. Rebman is a Marketing professional with a background in PublishingTechnologies, Communications and Graphic Design; specialty in branding & communications for social enterprise and NGO start-ups. Ms. Rebman ran a successful design services
Slide 24: Leadership Team
LEADERSHIP TEAM Sydney Cole - Executive Assistant & OfficeManager Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also worked for a Venture Capital company for five years as an executive assistant and office manager. From bookk
Slide 25: Advisory Board
ADVISORY BOARD Isaac Moss Isaac Moss B.Sc, M.Pub.Admin. has 30 years of experience in international corporate finance, public • Public Listing Advisor markets and business. Isaac was associated with an advisory group in Geneva Switzerland, providing • Investment banking advisor • CEO of a chemical c
Slide 26: Partners
PARTNERS CSE: PREV | OTCQB: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 26
Slide 27: Summary
SUMMARY Our Vision Our Vision is to be a leader in the preventive health sciences bringing innovative options for preventive and curative therapies ultilising organic and nature identical products. Keys to Success Management with extensive research experience, product development experience, deep co
Slide 28: Please Contact
PLEASE CONTACT Stephen Van Deventer Chairman & CEO Cell: 1 (604) 306-9669 Office: 1 (604) 416-7777 ext. 6230 [email protected] Deanna Kress Director of Corporate Communications & Investor Relations Cell: 1 (778) 999-6063 Office: 1 (604) 416 – 7777 ext. 6288 [email protected] CSE: PREV |
PreveCeutical Medical — Investor Presentation (September 2017) on 6ix